Search

Apply to be a Master Class mentor

Applications closed on July 15, 2024. There are two types of Master Class mentor: junior mentor and senior mentor. Before you apply, make sure you've read and understood the relevant eligibility criteria.

Read more

Clinical Research Training in Hematology

The CRTH 2025 call for applications is now closed. What is Clinical Research Training in Hematology (CRTH)?Clinical Research Training in Hematology (CRTH) provides early-career researchers with a unique, 9-month long training and mentoring experience.

Read more

ITA Airways discount

ITA Airways offers a 10% discount for EHA2025 Congress delegates.

Read more

“Complement-ing” positive outcomes during the COVID-19 pandemic

Dr Dimitrios Mastellos (@dmastellos)

The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.

Read more

How to apply for an EHA Innovation Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Innovation Grant application.

Read more

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.

Read more

EHA Congratulates EHA Research Grants 2022 Recipients

The Hague, May 30, 2022 – EHA congratulates eight talented researchers in hematology on their receipt of the EHA Research Grants 2022 after a rigorous selection process.

Read more

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1

 

Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more